Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome

被引:0
作者
Stephanie A. C. Halvorson
Erin Gilbert
R. Samuel Hopkins
Helen Liu
Charles Lopez
Michael Chu
Marie Martin
Brett Sheppard
机构
[1] Oregon Health & Science University,Division of Hospital Medicine, Department of Medicine
[2] Oregon Health & Science University,Department of Surgery
[3] Oregon Health & Science University,Department of Dermatology
[4] Oregon Health & Science University,Knight Cancer Institute
[5] Oregon Health & Science University,Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine
[6] Oregon Health & Science University,undefined
来源
Journal of General Internal Medicine | 2013年 / 28卷
关键词
glucagonoma; neuroendocrine tumors; necrolytic migratory erythema;
D O I
暂无
中图分类号
学科分类号
摘要
Glucagonomas are slow-growing, rare pancreatic neuroendocrine tumors. They may present with paraneoplastic phenomena known together as the “glucagonoma syndrome.” A hallmark sign of this syndrome is a rash known as necrolytic migratory erythema (NME). In this paper, the authors describe a patient with NME and other features of the glucagonoma syndrome. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. Surgical and medical treatment options are reviewed. When detected early, a glucagonoma is surgically curable. It is therefore imperative that clinicians recognize the glucagonoma syndrome in order to make an accurate diagnosis and refer for treatment.
引用
收藏
页码:1525 / 1529
页数:4
相关论文
共 94 条
[21]  
Wermers R(2004)Pancreatic endocrine tumors J Surg Res 120 139-85
[22]  
Fatourechi V(2007)Nuclear imaging of neuroendocrine tumours Best Pract Res, Clin Endocrinol Metab 21 69-4663
[23]  
Wynne A(1999)Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome J Clin Oncol 17 600-866
[24]  
Kvols L(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group J Clin Oncol 27 4656-86
[25]  
Lloyd R(2003)Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors Arch Surg 138 859-1505
[26]  
Stacpoole PW(2010)Advances in the treatment of gastroenteropancreatic neuroendocrine tumors Clin Exp Gastroenterol 3 79-513
[27]  
Alexander EK(2011)Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies Oncogene 30 1497-undefined
[28]  
Robinson M(2011)Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 501-undefined
[29]  
Staniec M(undefined)undefined undefined undefined undefined-undefined
[30]  
Dluhy RG(undefined)undefined undefined undefined undefined-undefined